- Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
- Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
- Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Sana Biotechnology Announces Pricing of Upsized Public Offering
- Sana Biotechnology Announces Proposed Public Offering of Common Stock
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
- Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
- Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
More ▼
Key statistics
On Friday, Sana Biotechnology Inc (SANA:NSQ) closed at 10.44, -13.00% below its 52-week high of 12.00, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.00 |
---|---|
High | 10.48 |
Low | 9.87 |
Bid | 10.22 |
Offer | 10.50 |
Previous close | 9.78 |
Average volume | 1.89m |
---|---|
Shares outstanding | 221.32m |
Free float | 201.27m |
P/E (TTM) | -- |
Market cap | 2.31bn USD |
EPS (TTM) | -1.46 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼